http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Evaluation of the implantable cardiac monitoring system in a mini-pig model
Ha-Young Jang,Sang-Hyun An,Jun-Sik Kim,Heejaung Kim,Gabbine Wee,Sang-Hyun Kim,Min-Soo Seo,Kyung-Ku Kang,Dae-Yong Han,Jung-Joo Rhyu,Sang-Kyoon Kim,Joon-Suk Park,Dong-Kyu Kim,Seonggon Kim,Taekwan Lee,Ch 한국실험동물학회 2014 한국실험동물학회 학술발표대회 논문집 Vol.2014 No.8
Efficacy test of CETP inhibitor candidates (DN2019) using CETP-apoB100 transgenic mice
Woori JO,Heejaung KIM,Hee Young LEE,Hyun Ho YUN,Mi Jeoung CHOE,Kyung-ku KANG,Min-soo Seo,Soong-Hyun Kim,Hee Jong Hwang,Eunhye Lee,Sungwoo Lee,Minsoo Song,Woo Suk KOH,Kil-Soo KIM 한국실험동물학회 2018 한국실험동물학회 학술발표대회 논문집 Vol.2018 No.7
Choi, Chan-Il,Lee, Young-Don,Kim, Heejaung,Kim, Seung Hyun,Suh-Kim, Haeyoung,Kim, Sung-Soo SAGE Publications 2013 Cell transplantation Vol.22 No.5
<P>Amyotrophic lateral sclerosis (ALS) is characterized by progressive dysfunction and degeneration of motor neurons in the central nervous system (CNS). In the absence of effective drug treatments for ALS, stem cell treatment has emerged as a candidate therapy for this disease. To date, however, there is no consensus protocol that stipulates stem cell types, transplantation timing, or frequency. Using an ALS mouse model carrying a high copy number of a mutant human superoxide dismutase-1 (SOD1)(G93A) transgene, we investigated the effect of neural induction on the innate therapeutic potential of mesenchymal stem cells (MSCs) in relation to preclinical transplantation parameters. In our study, the expression of monocyte chemoattractant protein-1 (MCP-1) was elevated in the ALS mouse spinal cord. Neural induction of MSCs with neurogenin 1 (Ngn1) upregulated the expression level of the MCP-1 receptor, CCR2, and enhanced the migration activity toward MCP-1 in vitro. Ngn1-expressing MSCs (MSCs-Ngn1) showed a corresponding increase in tropism to the CNS after systemic transplantation in ALS mice. Notably, MSCs-Ngn1 delayed disease onset if transplanted during preonset ages,whereas unprocessed MSCs failed to do so. If transplanted near the onset ages, a single treatment with MSCs-Ngn1 was sufficient to enhance motor functions during the symptomatic period (15?17 weeks), whereas unprocessed MSCs required repeated transplantation to achieve similar levels of motor function improvement. Our data indicate that systemically transplanted MSCs-Ngn1 can migrate to the CNS and exert beneficial effects on host neural cells for an extended period of time through paracrine functions, suggesting a potential benefit of neural induction of transplanted MSCs in long-term treatment of ALS.</P>